• Molecular NamePentoxifylline
  • SynonymEHT0201; pentoxifylline
  • Weight278.312
  • Drugbank_IDDB00806
  • ACS_NO6493-05-6
  • Show 2D model
  • LogP (experiment)0.29
  • LogP (predicted, AB/LogP v2.0)0.92
  • pka0.3
  • LogD (pH=7, predicted)0.92
  • Solubility (experiment)77 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.48
  • LogSw (predicted, AB/LogsW2.0)46.28
  • Sw (mg/ml) (predicted, ACD/Labs)9.3
  • No.of HBond Donors0
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds5
  • TPSA75.51
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt is used to treat intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.
  • Absorption_value95.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability25.0
  • Protein binding0.0
  • Volume of distribution (VD)4.2 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic and via erythrocytes
  • Half lifepentoxifylline, about 1 h, 5-hydroxy metabolite about 1 h; 1-(3-carboxypropyl)-3,7-dimethylxanthine, derived from urinary excretion data, about 1.4 h.
  • ExcretionMainly urine (<4% feces)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=1385 mg/kg